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Bio-Medical
Nano-Pervaporation Membrane With Heat Exchanger 
Generates Medical-Grade Water
A small system produces high-quality water using a heat exchanger that meets requirements for
evaporation of substances such as pharmaceuticals and vitamins.
Lyndon B. Johnson Space Center, Houston, Texas
A nanoporous membrane is used for
the pervaporation process in which
potable water is maintained, at atmos-
pheric pressure, on the feed side of the
membrane. The water enters the non-per-
vaporation (NPV) membrane device
where it is separated into two streams —
retentate water and permeated water. The
permeated pure water is removed by ap-
plying low vapor pressure on the perme-
ate side to create water vapor before con-
densation. This permeated water vapor is
subsequently condensed by coming in
contact with the cool surface of a heat ex-
changer with heat being recovered
through transfer to the feed water stream.
A thermoelectric heat exchanger is
used here to pump heat from the con-
densing surface to the feed water
stream. Because the temperature differ-
ential across this heat exchanger is rela-
tively small, the thermoelectric process
is highly energy efficient. This new heat
exchanger provides high surface area
for vapor condensation with control-
lable temperature on the hot and cold
sides to meet the operating temperature
requirements for the evaporation of sol-
vent-containing, heat-sensitive sub-
stances, such as pharmacological sub-
stances, vitamins, etc. 
The heat exchanger is a sandwich,
with the copper interface plates on both
sides of the heat pumps interfacing with
the radiators. The outside of the radia-
tors is insulated with two cover plates
bolted together to hold the entire heat
exchange unit together. Four heat-pump
units are connected in series and are
controlled by one circuit. The control
electronics are built around a standard
commercial voltage regulator. This was
chosen in part because it has a 6.2-volt
reference output that is needed for the
bridge circuit. The radiator on the in-
coming potable-water side is heating,
and the vapor side is cooling.
The NPV process can be operated at
close to room temperature, and is driven
by the space vacuum (provided by a sec-
ondary loop controlled by a secondary
vacuum valve with built-in redundancy
for safety) applied on the permeate side
with minimal energy consumption. A
primary valve controls the inlet space
vacuum. The nanoporous membrane
serves as a barrier, not only between liq-
uid and water vapor phases, but also be-
tween pure water and dissolved solids to
be removed. The nanopore selectively
adsorbs liquid water and excludes unde-
sirable constituents such as particles, mi-
crobes (e.g., bacteria), viruses, and
volatile organic compounds.
The system only requires a low-pres-
sure gradient across the membrane [<25
psi (≈172 kPa)] as compared to a high-
pressure gradient required for reverse
osmosis (RO) (>150 psi (≈1.03 MPa)], to
achieve high water-flow rate. As a result,
the novel membrane will not be prone
to the fouling issues that are commonly
seen in the RO system. The cross-flow
design can also allow the concentration
stream to sweep away retained molecules
and prevent the membrane surface from
clogging or fouling, making the system
able to deliver medical-grade water to
point of use. The overall process has no
moving parts and has low maintenance
requirements. 
This work was done by Chung-Yi Tsai and
Jerry Alexander of T3 Scientific Limited Lia-
bility for Johnson Space Center. For further in-
formation, contact the Johnson Commercial
Technology Office at (281) 483-3809. MSC-
24264-1/6-1
Micro-Organ Devices
Effects of drugs can be tested realistically, without experimentation on animals.
Lyndon B. Johnson Space Center, Houston, Texas
Micro-organ devices (MODs) are
being developed to satisfy an emerging
need for small, lightweight, repro-
ducible, biological-experimentation ap-
paratuses that are amenable to auto-
mated operation and that impose
minimal demands for resources (princi-
pally, power and fluids). MODs are in-
tended to overcome major disadvan-
tages of conventional in vitro and
conventional in vivo experimentation
for purposes of investigating effects of
medicines, toxins, and possibly other
foreign substances.
Conventional in vitro cell cultures do
not mimic the complex environments to
which toxins and medicines are subjected
in living organisms. Conventional in vivo
studies in non-human animals can ac-
count for complex intercellular and inter-
tissue effects not observable in in vitro
tests, but experimentation on animals is
expensive, labor intensive, time-consum-
ing, and unpopular. Moreover, cross-
species extrapolation of toxicity and phar-
macokinetic characteristics is problem-
atic. In contrast, because MODs could
host life-like miniature assemblies of
human cells, the effects observed in tests
performed in MODs could be extrapo-
lated more readily to humans than could
effects observed in conventional in vitro
cell cultures, making it possible to reduce
or eliminate experimentation on animals.
In simplest terms, a MOD is a mi-
crofluidic device containing a variety of
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microstructures and assemblies of cells
(see figure), all designed to mimic a
complex in vivo microenvironment by
replicating one or more in vivo
micro-organ structures, the architec-
tures and composition of the extracellu-
lar matrices in the organs of interest,
and the in vivo fluid flows. In addition to
microscopic flow channels, a MOD con-
tains one or more micro-organ wells
containing cells residing in microscopic
extracellular matrices and/or scaffolds,
the shapes and compositions of which
enable replication of the corresponding
in vivo cell assemblies and flows.
Once the basic microfluidic device in-
frastructure of a MOD containing micro-
organ wells and flow channels has been
fabricated, single cells or multiple cells
of the same type or different types
needed for a given micro-organ are en-
capsulated or suspended in a solution
that may contain micro-organ-specific
extracellular matrix molecules and scaf-
folding. The suspension or solution is
placed in a syringe that is part of a com-
puter-controlled apparatus; under com-
puter control, cells and any extracellular
matrix material are dispensed as the sy-
ringe is moved, thereby effectively print-
ing a unitary three-dimensional assem-
bly of cells and extracellular matrix ma-
terial into a micro-organ well. The di-
mensions of each printed micro-organ
are chosen so as not to exceed optimum
dimensions for perfusion of cells with
nutrient fluid, exchange of gases be-
tween the cells and the nutrient fluid,
and removal of non-gaseous cell wastes
in the nutrient flow.
This work was done by Steven R. Gonda
and Julia Leslie of Johnson Space Center;
Robert C. Chang, Binil Starly, and Wei Sun
of Drexel University; Christopher Culbertson
of Kansas State University; and Heidi
Holtorf of USRA. For further information,
contact the JSC Innovation Partnerships Of-
fice at (281) 483-3809. 
This invention is owned by NASA, and a
patent application has been filed. Inquiries
concerning nonexclusive or exclusive license
for its commercial development should be ad-
dressed to the Patent Counsel, Johnson
Space Center, (281) 483-1003. Refer to
MSC-23988-1.
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This Simple Example MOD is designed for use in monitoring (1) conversion of a drug from inactive
form A to active form A' in the liver and (2) indirectly monitoring the effect of A' on a bone by mon-
itoring the concentration of A", which is a tertiary metabolite form of the drug. 
